Aenova Expands its Refrigerated Logistics for Biologics
Aenova is investing in a new cold storage infrastructure at its sterile site in Latina (Italy). With the state-of-the-art facility, Aenova offers its customers an integrated end-to-end supply chain solution for biologics and other temperature-sensitive pharmaceutical products.
The new warehouse is integrated into the existing building and represents a strategic expansion of Aenova 's cold chain infrastructure. Construction began at the start of this year, with official approval and initial operation expected in the first quarter of 2026.
The approximately 6,500m3 warehouse offers a total capacity of 1,300 pallet spaces with around 100 pallet spaces for packing, shipping and final product preparation. The facility is designed to maintain a controlled temperature range of 2-8 °C, which is continuously monitored and recorded via a Supervisory Control and Data Acquisition (SCADA) system to ensure full compliance with current Good Manufacturing Practices (cGMP).
The warehouse is fully automated and has an integrated digital system for precise location tracking and pallet movement. Goods are transported between the production and storage areas using an automated guided vehicle (AGV) and all time of refrigeration (TOR) data is recorded digitally. To ensure uninterrupted operation, the facility is equipped with two independent cooling systems that support each other, ensuring robust business continuity. In addition, the warehouse features state-of-the-art technologies that improve energy efficiency and support Aenova's sustainability goals. A dedicated freezer area for the storage of pharmaceuticals is also integrated.
“This expansion significantly enhances our biologics and sterile drug product offering,” says Paolo Abbate, Managing Director at the Aenova site in Latina. “By integrating cold chain storage directly into our manufacturing site, we can now offer our customers secure and streamlined logistics; this is a real competitive advantage in terms of speed, reliability, and compliance.”
The new facility is designed to support a wide range of cold chain products without requiring special adaptations for specific APIs or countries, making it a versatile solution for global pharmaceutical partners.
This development further strengthens Aenova Latina’s position as a CDMO partner in sterile manufacturing, offering a comprehensive suite of services from drug substance to finished product, all in one place. This paves the way for the expansion of the site with an additional fill & finish line for biologics planned for the upcoming years.
